← All Shattuck Labs, INC filings

Shattuck Labs, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
STTK
Shattuck Labs, INC
10-K: Shattuck Labs Advances SL-325 to Phase 2, Narrows 2025 Net Loss
Shattuck Labs, a clinical-stage biotech, is advancing its lead DR3 blocking antibody, SL-325, into Phase 2 for Crohn's Disease while reporting a reduced net loss for fiscal year 2025.
NASDAQ
STTK
Shattuck Labs, INC
10-K/A: Shattuck Labs Files Amendment No. 2 to 2024 Annual Report on Form 10-K/A
Shattuck Labs files an amendment to its 2024 Annual Report on Form 10-K/A solely to include certain XBRL interactive data that was inadvertently omitted in Amendment No. 1.
NASDAQ
STTK
Shattuck Labs, INC
10-K/A: Shattuck Labs Files Amendment to 2024 Annual Report, Providing Detailed Information on Directors, Executive Compensation, and Corporate Governance
Shattuck Labs files an amendment to its 2024 Annual Report on Form 10-K/A to include information required by Items 10 through 14 of Part III, covering directors, executive compensation, security ownership, related transactions, and principal accountant fees.
NASDAQ
STTK
Shattuck Labs, INC
10-K: Shattuck Labs Focuses on DR3 Antibody Program, Files 10-K Report
Shattuck Labs' 2024 10-K filing highlights a strategic shift towards its SL-325 DR3 antagonist antibody program for inflammatory bowel disease, alongside financial results and risk factors.
NASDAQ
STTK
Shattuck Labs, INC
10-K: Shattuck Labs Outlines Stock Option and Compensation Plans in SEC Filing
Shattuck Labs details its 2020 Equity Incentive Plan and related stock option agreements, alongside its non-employee director compensation policy, in a recent SEC filing.